Mardi M Algandaby1, Randa M Breikaa2, Basma G Eid3, Thikrayat A Neamatallah3, Ashraf B Abdel-Naim4, Osama M Ashour5. 1. Medicinal Plants Research Group, Deanship of Scientific Research, King Abdulaziz University, Jeddah, Saudi Arabia; Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia. 2. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. 3. Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia. 4. Medicinal Plants Research Group, Deanship of Scientific Research, King Abdulaziz University, Jeddah, Saudi Arabia; Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia. 5. Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia. Electronic address: Ommohamed@kau.edu.sa.
Abstract
BACKGROUND: Liver fibrosis is a major health problem. The current study evaluated the potential of icariin (ICA) to guard against thioacetamide (TAA)-induced liver fibrosis in rats. METHODS: Four groups of male rats were treated as follows: group 1 was the control group, group 2 was given TAA (200mg/kg), group 3 was administered ICA (50mg/kg) and TAA (200mg/kg), and group 4 was given ICA (50mg/kg) alone. Animal treatment was continued for four weeks. RESULTS: Co-administration of ICA guarded against TAA hepatotoxicity as indicated by significant inhibition in the rise of serum ALT and AST activities and albumin concentrations. This was accompanied by inhibition of reduced glutathione depletion, superoxide dismutase exhaustion, and lipid peroxide accumulation. In addition, ICA inhibited the pathological alterations in liver architecture induced by TAA. The antifibrotic activity of ICA was verified by reduced hepatic collagen deposition in liver sections stained with Masson's trichrome and hepatic Col-1α mRNA and hydroxyproline contents compared to the TAA-treated group. The antiangiogenic activity of ICA was evidenced by lowered levels of mRNA of Ang-1 and protein expression of VEGF, PDGF-β, and CTGF immunohistochemically. Further, the anti-autophagic property of ICA was evidenced by amelioration of the decrease in mTOR and p70S6 kinase expression and an increase in TLR4, NFκB, IL1-β, and COX-2 immunohistochemically. Moreover, ICA antagonized the increase in HMGB1, TGF-β, and Beclin-1 and the decrease in BAMBI hepatic mRNA levels. CONCLUSIONS: ICA inhibits TAA-induced liver fibrosis in rats, possibly via inhibition of angiogenesis and autophagy.
BACKGROUND:Liver fibrosis is a major health problem. The current study evaluated the potential of icariin (ICA) to guard against thioacetamide (TAA)-induced liver fibrosis in rats. METHODS: Four groups of male rats were treated as follows: group 1 was the control group, group 2 was given TAA (200mg/kg), group 3 was administered ICA (50mg/kg) and TAA (200mg/kg), and group 4 was given ICA (50mg/kg) alone. Animal treatment was continued for four weeks. RESULTS: Co-administration of ICA guarded against TAA hepatotoxicity as indicated by significant inhibition in the rise of serum ALT and AST activities and albumin concentrations. This was accompanied by inhibition of reduced glutathione depletion, superoxide dismutase exhaustion, and lipid peroxide accumulation. In addition, ICA inhibited the pathological alterations in liver architecture induced by TAA. The antifibrotic activity of ICA was verified by reduced hepatic collagen deposition in liver sections stained with Masson's trichrome and hepatic Col-1α mRNA and hydroxyproline contents compared to the TAA-treated group. The antiangiogenic activity of ICA was evidenced by lowered levels of mRNA of Ang-1 and protein expression of VEGF, PDGF-β, and CTGF immunohistochemically. Further, the anti-autophagic property of ICA was evidenced by amelioration of the decrease in mTOR and p70S6 kinase expression and an increase in TLR4, NFκB, IL1-β, and COX-2 immunohistochemically. Moreover, ICA antagonized the increase in HMGB1, TGF-β, and Beclin-1 and the decrease in BAMBI hepatic mRNA levels. CONCLUSIONS:ICA inhibits TAA-induced liver fibrosis in rats, possibly via inhibition of angiogenesis and autophagy.
Authors: Wael Mahmoud Aboulthana; Nagwa Ibrahim Omar; Enas Ahmed Hasan; Kawkab A Ahmed; Ahmed Mahmoud Youssef Journal: Asian Pac J Cancer Prev Date: 2022-01-01
Authors: Woonhyeok Jeong; Chae Eun Yang; Tai Suk Roh; Jun Hyung Kim; Ju Hee Lee; Won Jai Lee Journal: Int J Mol Sci Date: 2017-08-03 Impact factor: 5.923
Authors: Hui Zhang; Khalid Mehmood; Kun Li; Mujeeb U Rehman; Xiong Jiang; Shucheng Huang; Lei Wang; Lihong Zhang; Xiaole Tong; Fazul Nabi; Wangyuan Yao; Muhammad K Iqbal; Muhammad Shahzad; Jiakui Li Journal: Front Pharmacol Date: 2018-02-23 Impact factor: 5.810
Authors: Mohammed W Al-Rabia; Nabil A Alhakamy; Osama A A Ahmed; Khalid Eljaaly; Ahmed L Aloafi; Ahmed Mostafa; Hani Z Asfour; Ahmed A Aldarmahi; Khaled M Darwish; Tarek S Ibrahim; Usama A Fahmy Journal: Pharmaceutics Date: 2021-02-26 Impact factor: 6.321
Authors: Nabil A Alhakamy; Usama A Fahmy; Shaimaa M Badr-Eldin; Osama A A Ahmed; Hani Z Asfour; Hibah M Aldawsari; Mardi M Algandaby; Basma G Eid; Ashraf B Abdel-Naim; Zuhier A Awan; Nabil K Alruwaili; Amir I Mohamed Journal: Pharmaceutics Date: 2020-04-11 Impact factor: 6.321